Display options
Share it on

Transl Med UniSa. 2016 May 16;14:54-63. eCollection 2016 May.

Bivalirudin in Patients Undergoing PCI: State of Art and Future Perspectives.

Translational medicine @ UniSa

G Galasso, M Mirra, G De Luca, F Piscione

Affiliations

  1. Department of Medicine and Surgery, University of Salerno, Salerno, Italy.
  2. Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.
  3. Division of Cardiology, AOU Maggiore della Carità-Eastern Piedmont University, Novara, Italy.

PMID: 27326396 PMCID: PMC4912339

Abstract

Acute coronary syndrome (ACS) represents the most common cause of death worldwide. Percutaneous coronary intervention (PCI) is the management of choice in patients with ACS and occurrence of intra-procedural thrombotic complications are an independent predictor of mortality and other major adverse cardiovascular events in patients undergoing PCI. According to current guideline, anticoagulation therapy is indicated during PCI in order to reduce the risk of thrombotic complications such as stent thrombosis. Among currently available anticoagulant drugs, bivalirudin demonstrates a lower incidence of bleeding risk, despite it is associated with an increased risk of stent thrombosis. The aim of this paper is to discuss the pharmacology of bivalirudin and the clinical evidences of its use in patients undergoing PCI for ACS.

Keywords: anticoagulant; bivalirudin; bleeding; myocardial infarction; percutaneous coronary intervention

References

  1. JAMA. 2015 Apr 7;313(13):1336-46 - PubMed
  2. PLoS One. 2015 May 26;10 (5):e0127832 - PubMed
  3. Lancet. 2009 Oct 3;374(9696):1149-59 - PubMed
  4. JACC Cardiovasc Interv. 2015 Mar;8(3):414-23 - PubMed
  5. EuroIntervention. 2015 Jun;11(2):196-203 - PubMed
  6. N Engl J Med. 2013 Dec 5;369(23 ):2207-17 - PubMed
  7. J Interv Cardiol. 2013 Apr;26(2):107-13 - PubMed
  8. J Am Coll Cardiol. 2006 Jun 20;47(12 ):2364-73 - PubMed
  9. Circulation. 2013 Jan 29;127(4):529-55 - PubMed
  10. Am J Cardiol. 2012 Aug 15;110(4):478-84 - PubMed
  11. Lancet. 2011 Jun 25;377(9784):2193-204 - PubMed
  12. Lancet. 2007 Mar 17;369(9565):907-19 - PubMed
  13. EuroIntervention. 2013 Aug 22;9(4):430-6 - PubMed
  14. J Am Coll Cardiol. 2007 Aug 14;50(7):573-83 - PubMed
  15. Expert Opin Pharmacother. 2002 Jun;3(6):777-88 - PubMed
  16. Eur Heart J. 2011 Dec;32(23):2999-3054 - PubMed
  17. Lancet. 2014 Aug 16;384(9943):599-606 - PubMed
  18. Anesth Analg. 2003 May;96(5):1316-9, table of contents - PubMed
  19. Thromb Haemost. 2015 Nov;114(5):933-44 - PubMed
  20. Eur Heart J. 2012 Oct;33(20):2569-619 - PubMed
  21. N Engl J Med. 2011 Nov 24;365(21):1980-9 - PubMed
  22. Clin Cardiol. 2014 May;37(5):270-6 - PubMed
  23. N Engl J Med. 2008 May 22;358(21):2218-30 - PubMed
  24. Pharmacotherapy. 2002 Jun;22(6 Pt 2):105S-111S - PubMed
  25. N Engl J Med. 1995 Sep 21;333(12 ):764-9 - PubMed
  26. Lancet. 2015 Jun 20;385(9986):2465-76 - PubMed
  27. Am J Cardiol. 2009 Nov 1;104(9):1222-8 - PubMed
  28. N Engl J Med. 2006 Nov 23;355(21):2203-16 - PubMed
  29. Lancet. 2014 Nov 22;384(9957):1849-58 - PubMed
  30. Leukemia. 2012 Oct;26(10 ):2300-1 - PubMed
  31. Eur Heart J. 2012 Oct;33(20):2551-67 - PubMed
  32. J Am Coll Cardiol. 2012 Dec 18;60(24):e44-e164 - PubMed
  33. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228 - PubMed
  34. N Engl J Med. 2008 Aug 14;359(7):688-96 - PubMed
  35. Eur Heart J. 2014 Oct 1;35(37):2541-619 - PubMed
  36. Thromb Haemost. 2015 May;113(5):1010-20 - PubMed
  37. JAMA. 2004 Aug 11;292(6):696-703 - PubMed

Publication Types